Comparative Pharmacology
Head-to-head clinical analysis: ENVARSUS XR versus GENGRAF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENVARSUS XR versus GENGRAF.
ENVARSUS XR vs GENGRAF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
5-15 mg/kg/day orally in divided doses every 12 hours.
None Documented
None Documented
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
Category C
Category C
Calcineurin Inhibitor Immunosuppressant
Calcineurin Inhibitor Immunosuppressant